Tepezza Hearing Loss Lawsuit
teprotumumab-trbw · Horizon Therapeutics (Amgen) · updated June 2026
Tepezza, an infusion for thyroid eye disease, faces lawsuits alleging it caused permanent hearing loss and tinnitus that the label failed to adequately warn about.
This page is general information about ongoing litigation and FDA safety actions — not medical or legal advice, and not a statement that Tepezza caused any injury. Allegations described here are claims that have not been proven in court. Always consult a licensed professional.
What the lawsuits allege
Plaintiffs allege the manufacturer failed to adequately warn that Tepezza (teprotumumab) can cause permanent or long-term hearing loss and tinnitus.
- Hearing loss
- Tinnitus
FDA action
Tepezza's prescribing information lists hearing impairment among its warnings; plaintiffs contend the label understated the risk of permanent hearing loss.
Verify against the current FDA-approved label: Tepezza label on DailyMed (U.S. NLM).
Where the litigation stands
As of mid-2026, roughly 280 cases are consolidated in MDL 3079 (Northern District of Illinois). The court vacated the bellwether (test) trial deadlines amid global-settlement negotiations, so no trial date is firmly set — treat any specific date as subject to change.
Case counts and MDL status are published by the U.S. Judicial Panel on Multidistrict Litigation — JPML pending MDLs. Any figure not on the court record is attributed to the secondary legal-press links below.
Who may be affected
The Tepezza lawsuits are brought by people who say they used Tepezza (teprotumumab-trbw) and were later diagnosed with one or more of the alleged injuries above. Whether any individual situation could support a claim depends on the specific facts, the medical records, and each state's filing deadline (statute of limitations) — which can expire, so timing matters. Only a licensed attorney can evaluate a specific case. This page is general information, not legal advice.
Frequently asked
- What is the Tepezza lawsuit about?
- Plaintiffs allege the manufacturer failed to adequately warn that Tepezza (teprotumumab) can cause permanent or long-term hearing loss and tinnitus. As of mid-2026, roughly 280 cases are consolidated in MDL 3079 (Northern District of Illinois). The court vacated the bellwether (test) trial deadlines amid global-settlement negotiations, so no trial date is firmly set — treat any specific date as subject to change.
- What injuries are alleged in the Tepezza lawsuits?
- Lawsuits allege hearing loss, tinnitus. These are allegations; a court has not found that Tepezza causes them.
- Has the FDA acted on Tepezza?
- Tepezza's prescribing information lists hearing impairment among its warnings; plaintiffs contend the label understated the risk of permanent hearing loss.
- Is there a deadline to file a Tepezza lawsuit?
- Yes — every state sets a filing deadline (statute of limitations) for product-injury claims, often running from the date of injury or diagnosis, and once it passes a claim is usually barred. The exact window varies by state and circumstances, so anyone considering a claim should check with a licensed attorney promptly. This is general information, not legal advice.